Bicara Therapeutics Inc. Common Stock Q3 2026 Earnings Call Summary Moby Intelligence Mon, November 9, 2026 at 12:55 PM EST 4 min read NVDA -5.34% BCAX +9.10% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management attributes FICERA's clinical potential to its dual inhibition of EGFR and TGF-beta, which targets the immune-suppressive tumor microenvironment specific to HPV-negative disease.
The company is focusing exclusively on HPV-negative head and neck cancer because these patients represent 80% to 90% of cases and face the worst prognosis with limited treatment options.
Management highlights that 80% of responders in Phase Ib showed tumor shrinkage of 80% or more, positioning the drug as a potential chemo-sparing regimen for patients with bulky tumors.
Recent positive peer data in the space is viewed as validation for the new class of EGFR-targeted therapies, strengthening management's conviction in their TGF-beta-driven approach.
The strategic decision to maintain a blinded trial design for FORTIFI-HN01 is intended to preserve regulatory integrity and competitive positioning compared to open-label peer studies.
Operational focus has shifted toward building commercial and medical infrastructure, including payer and access strategies, to support a potential U.S. launch.
Management emphasizes that depth and durability of response are the primary drivers for physician treatment choice, which they believe will differentiate FICERA from standard of care.
Bicara confirmed it will incorporate an interim overall survival analysis into the FORTIFI-HN01 study to optimize speed to market and support a maximally competitive commercial label.
Top-line interim analysis for the pivotal FORTIFI-HN01 study remains on track for the middle of next year.
The company plans to present Phase Ib expansion data for metastatic colorectal cancer in January to evaluate safety and efficacy signals for potential earlier-line combinations.
Cash runway is projected into the first half of 2029, covering the final overall survival analysis, BLA filing, and initial commercial launch investments.
The FORTIFI-FLEX study is evaluating a less frequent every 3-week dosing regimen to enhance patient convenience and further differentiate the product profile at launch.
The company achieved substantial enrollment in the FORTIFI-HN01 trial, a key milestone enabling the planned mid-2027 interim analysis.
Management confirmed the trial is adequately sized at 650 patients for an HPV-negative only population and does not require upsizing to include the new interim survival analysis.
Research and development expenses increased to $56.5 million, driven by costs for the FORTIFI-HN01 and FORTIFI-FLEX trials, dose expansion cohorts, and increased personnel costs.
Management emphasized that HPV-negative patients have distinct biology and worse outcomes, making subgroup-specific data essential for interpreting clinical benefit.
They noted that HPV-positive patients historically live longer, which can skew overall survival results in mixed-population trials.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
While acknowledging the benefits of being first, management believes physicians will ultimately choose the therapy with the most compelling depth, durability, and survival data.
They anticipate less than a year of difference between their potential approval and the first-mover, which historically allows for competitive peak share uptake.
Management expects minimal impact on the FORTIFI trial because the study is blinded and the current approval for amivantamab covers a different patient population.
They noted that much of their enrollment is outside the U.S. where the recent approval does not yet exist.
The trial was prospectively designed with 650 patients to provide optionality for an interim OS analysis without needing to increase the patient count.
Management believes the depth and durability seen in Phase Ib will translate into a meaningful survival benefit compared to the standard of care.
Management identified response rates of 10% to 15% from recent peer studies as relevant benchmarks for their third-line metastatic colorectal cancer data presentation in January.
The primary goal for the CRC data is to confirm a consistent safety profile that supports moving into earlier lines of therapy.
